In Vitro Activity of Solithromycin against Bordetella pertussis – An Emerging Respiratory Pathogen.

There has been an increase in the number of pertussis cases reported since the introduction of the acellular pertussis vaccine. While children that present with pertussis have a characteristic whooping cough, adults can simply have a persistent, non-specific cough and remain undiagnosed. Macrolide antibiotics, such as azithromycin, are the currently recommended treatment for pertussis. Solithromycin is a new macrolide and the first fluoroketolide, with broad activity against a wide spectrum of bacterial pathogens and has completed clinical development for community-acquired bacterial pneumonia (CABP). This study reports the potent in vitro activity of solithromycin against a collection of recent isolates of Bordetella pertussis.

Authors:Hardy DJ1, Vicino D2, Fernandes P3.
Journal:Antimicrob Agents Chemother. 2016
Link:http://www.ncbi.nlm.nih.gov/pubmed/27620481